Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients
about
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLCClinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement.Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.Thyroid metastasis from lung adenocarcinoma with EML4-ALK rearrangementMeta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC.
P2860
Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@ast
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@en
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@nl
type
label
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@ast
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@en
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@nl
prefLabel
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@ast
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@en
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@nl
P2093
P2860
P1433
P1476
Efficacy and safety of crizoti ...... mall cell lung cancer patients
@en
P2093
Guangli Xiao
Tongyu Lin
Yabing Cao
P2860
P304
P356
10.1371/JOURNAL.PONE.0114008
P407
P577
2014-12-12T00:00:00Z